European Commission approves idecabtagene vicleucel for the treatment of triple-class-exposed RRMM
On March 20, 2024, the European Commission granted approval to ide-cel for the treatment of triple-class-exposed RRMM with two or more prior therapies, including an IMiD, PI, and an anti-CD38 antibody with subsequent disease progression.